Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Dublin, Aug. 16, 2017 -- The "R&D and Business Tracker for Antibody-Drug Conjugates" newsletter has been added to Research and Markets' offering.
This information service about Antibody-Drug Conjugates (ADCs) delivers 12 monthly update reports in pdf format by e-mail straight to your desk and provides online access to the author's R&D database for the subject field of the service during the one-year subscription period. Credentials to access the online database will be sent by e-mail within 24 hours after purchase.
This product consists of:
- 12 monthly update reports in pdf format delivered by e-mail; and
- Online access to ADC R&D database during the 1-year subscription period.
The monthly update report about Antibody-Drug Conjugates contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
Business Tracker for:
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
Clinical Trial Tracker
Scientific Publication Tracker
Featured Cell Therapy Profile
Featured Company Profile
Featured Target or Technology Pipeline
For more information about this newsletter visit https://www.researchandmarkets.com/research/xvprdr/randd_and
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs
